Sonja Babovic

The Lin28b–let-7–Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells

Mouse haematopoietic stem cells (HSCs) undergo a postnatal transition in several properties, including a marked reduction in their self-renewal activity. We now show that the developmentally timed change in this key function of HSCs is associated with their decreased expression of Lin28b and an accompanying increase in their let-7 microRNA levels. Lentivirus-mediated overexpression of Lin28 in adult HSCs elevates their self-renewal activity in transplanted irradiated hosts, as does overexpression of Hmga2, a well-established let-7 target that is upregulated in fetal HSCs. Conversely, HSCs from fetal Hmga2−/− mice do not exhibit the heightened self-renewal activity that is characteristic of wild-type fetal HSCs. Interestingly, overexpression of Hmga2 in adult HSCs does not mimic the ability of elevated Lin28 to activate a fetal lymphoid differentiation program. Thus, Lin28b may act as a master regulator of developmentally timed changes in HSC programs with Hmga2 serving as its specific downstream modulator of HSC self-renewal potential.

Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia

From an shRNA screen, we identified ClpP as a member of the mitochondrial proteome whose knockdown reduced the viability of K562 leukemic cells. Expression of this mitochondrial protease that has structural similarity to the cytoplasmic proteosome is increased in leukemic cells from approximately half of all patients with AML. Genetic or chemical inhibition of ClpP killed cells from both human AML cell lines and primary samples in which the cells showed elevated ClpP expression but did not affect their normal counterparts. Importantly, Clpp knockout mice were viable with normal hematopoiesis. Mechanistically, we found that ClpP interacts with mitochondrial respiratory chain proteins and metabolic enzymes, and knockdown of ClpP in leukemic cells inhibited oxidative phosphorylation and mitochondrial metabolism.

Hierarchical organization of fetal and adult hematopoietic stem cells.

Mammalian hematopoiesis is a hierarchically organized process in which all types of mature blood cells are continuously generated from more primitive cells that lack any morphological evidence of differentiation. However, it is now accepted that this morphologically homogeneous precursor population consists of multiple distinct subsets of cells. The most primitive of these are defined by their ability to produce similarly undifferentiated progeny through many cell divisions, in addition to generating cells with activated differentiation programs. The term hematopoietic stem cell (HSC) is now conventionally restricted to cells with this long-term self-sustaining ability. Nevertheless, clonal tracking studies have revealed significant heterogeneity in the behavior of such stringently defined HSCs. Moreover, superimposed on the heterogeneous behavior that can be elicited from the HSCs present at any given time during development are additional differences that distinguish HSCs at different times both before and after birth. The latter include changes in the representation of HSCs that display specific differentiation programs, as well as changes in their turnover and self-renewal control. Here, we summarize recent studies characterizing these developmental changes, some of the mechanisms that control them, and their potential relevance to understanding age-associated differences in leukemia as well as normal hematopoiesis.

Distinct Stromal Cell Factor Combinations Can Separately Control Hematopoietic Stem Cell Survival, Proliferation, and Self-Renewal

Summary Hematopoietic stem cells (HSCs) are identified by their ability to sustain prolonged blood cell production in vivo, although recent evidence suggests that durable self-renewal (DSR) is shared by HSC subtypes with distinct self-perpetuating differentiation programs. Net expansions of DSR-HSCs occur in vivo, but molecularly defined conditions that support similar responses in vitro are lacking. We hypothesized that this might require a combination of factors that differentially promote HSC viability, proliferation, and self-renewal. We now demonstrate that HSC survival and maintenance of DSR potential are variably supported by different Steel factor (SF)-containing cocktails with similar HSC-mitogenic activities. In addition, stromal cells produce other factors, including nerve growth factor and collagen 1, that can antagonize the apoptosis of initially quiescent adult HSCs and, in combination with SF and interleukin-11, produce >15-fold net expansions of DSR-HSCs ex vivo within 7 days. These findings point to the molecular basis of HSC control and expansion.

A Dominant-Negative Isoform of IKAROS Expands Primitive Normal Human Hematopoietic Cells

Summary Disrupted IKAROS activity is a recurrent feature of some human leukemias, but effects on normal human hematopoietic cells are largely unknown. Here, we used lentivirally mediated expression of a dominant-negative isoform of IKAROS (IK6) to block normal IKAROS activity in primitive human cord blood cells and their progeny. This produced a marked (10-fold) increase in serially transplantable multipotent IK6+ cells as well as increased outputs of normally differentiating B cells and granulocytes in transplanted immunodeficient mice, without producing leukemia. Accompanying T/natural killer (NK) cell outputs were unaltered, and erythroid and platelet production was reduced. Mechanistically, IK6 specifically increased human granulopoietic progenitor sensitivity to two growth factors and activated CREB and its targets (c-FOS and Cyclin B1). In more primitive human cells, IK6 prematurely initiated a B cell transcriptional program without affecting the hematopoietic stem cell-associated gene expression profile. Some of these effects were species specific, thus identifying novel roles of IKAROS in regulating normal human hematopoietic cells.

Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals

This is a commentary on how the trade-related aspects of intellectual property rights (TRIPS) agreement has impacted India as a supplier of generic antiretrovirals (ARVs). We provide a systematic review of the issues related to the TRIPS agreement that affects India. This includes discussion around (a) the legal landscape underpinning India as a supplier of generic ARVs; (b) supply of second-line ARVs; and (c) the future of generic drug production in India. The proclamation into force of TRIPS-compliant intellectual property law in India is likely to affect its position as a supplier of affordable ARVs, especially drugs brought to market after 2005. Currently, mechanisms exist for the generic production of almost all ARVs in India, including second-line drugs; however, the manufacture of these drugs by generic pharmaceutical companies may require additional market incentives. Compulsory licensing may emerge as an additional mechanism by which India can provide affordable versions of patented drugs to Least Developed Countries (LDCs).

Increasing access to essential medicines: Diversifying Canada's approach

Improving the health of lesser-developed countries has received a great deal of attention, but very few if any strategies have proven effective in the long term, and many that are suggested by the international community are temporary and unsustainable.1 Increasing access to essential medicines by addressing barriers arising from intellectual property rights and trade law agreements has been a popular avenue to achieve improvements in global health; Canada has focused on adopting legislation that eases patent restrictions to lower the cost of medicines in the global South.2 Canada’s Access to Medicines Regime (CAMR) is intended to effect systemic change by addressing access barriers associated with the high cost of patented drugs, by providing a legal avenue for Canadian drug manufacturers to bypass patent barriers to export low-cost medicines to developing countries.3 Canada has been perceived as a leader in this area, but the unfortunate reality is that the country continues to struggle to amend this unworkable piece of legislation that at present does not increase access to essential medicines.4,5 The awareness that has been raised and the attention that Canada has focused on the issue of access to essential medicines put the country in a unique position to advocate for solutions that would build off and complement the progress made in intellectual property rights and trade law to address potentially more significant barriers, such as the lack of local pharmaceutical manufacturing capacity in developing countries.6

Dominant-negative IKAROS enhances IL-3-stimulated signaling in wild-type but not BCR-ABL1+ mouse BA/F3 cells

Inactivating mutations in IKZF1, the gene that encodes the transcription factor IKAROS, are recurrent in poor-prognosis human B-cell leukemias, in which these mutations co-exist with BCR-ABL1 or other genetic changes that activate similar intracellular signaling pathways. However, little is known about the mechanism(s) by which loss of IKAROS activity may co-operate with BCR-ABL1 to transform lymphoid cells. To investigate this question, we used expression of a dominant-negative isoform of IKAROS (IK6) to suppress endogenous IKAROS activity in the interleukin-3 (IL-3)-dependent mouse pro-B BA/F3 cell line and in an IL-3-independent BCR-ABL1(+) derivative. We then used intracellular phospho-flow cytometry to assess the effects of BCR-ABL1 and IK6, alone and in combination, on the signaling state of the cells before and after their stimulation with IL-3. BCR-ABL1 and IK6 each produced a constitutively activated signaling phenotype and also enhanced the signaling responses of BA/F3 cells to IL-3. These effects, however, were neither equivalent nor additive, and IK6 alone was insufficient to confer the IL-3-independent growth characteristic of BCR-ABL1(+) BA/F3 cells. In addition to its effects on lymphoid cells, IK6 also induced constitutively activated signaling in a subset of myeloid leukemia cell lines. Together, these studies indicate an ability of IK6 to enhance intracellular signaling in both lymphoid and myeloid cells, but not to synergize with BCR-ABL1 in this model system.